AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Try a sample question
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
mecamylamine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 1646 | 60-40-2 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A nicotinic antagonist that is well absorbed from the gastrointestinal tract and crosses the blood-brain barrier. Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 0 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 212 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 50 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 1.75 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 99 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 0.128 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 2.128 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 3.908 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 1.841 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 72.360 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 59.550 | % | High | 1 |
| herg | hERG pIC50 | 4.277 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 2.710 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 12.331 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 66.610 | % | High | 1 |
| kinase-safety-class | ACVR2B,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,JAK3,MAP2K6,MAPK10,MAPK7,NTRK2,PDK2,PDK4,PRKDC,TEK,TGFBR1,ZAP70 | 25 | |||
| kinase-selectivity-class | EIF2AK3,PDK2 | 2 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 2.793 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 41.976 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 71.810 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 1.393 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 56.360 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 20.797 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 83.750 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 79.660 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 669.885 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| March 1, 1956 | FDA |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | C02BB01 | CARDIOVASCULAR SYSTEM ANTIHYPERTENSIVES ANTIADRENERGIC AGENTS, GANGLION-BLOCKING Secondary and tertiary amines |
| MeSH PA | D000959 | Antihypertensive Agents |
| MeSH PA | D002317 | Cardiovascular Agents |
| MeSH PA | D005730 | Ganglionic Blockers |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018678 | Cholinergic Agents |
| MeSH PA | D018680 | Cholinergic Antagonists |
| MeSH PA | D018733 | Nicotinic Antagonists |
| CHEBI has role | CHEBI:35469 | antidepressant |
| CHEBI has role | CHEBI:35674 | antihypertensive agent |
| CHEBI has role | CHEBI:66981 | ophthalmology drug |
| CHEBI has role | CHEBI:176497 | geroprotector |
| FDA EPC | N0000175641 | Autonomic Ganglionic Blocker |
| FDA PE | N0000175644 | Decreased Autonomic Ganglionic Activity |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Hypertensive disorder | indication | 38341003 | DOID:10763 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 10.86 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Neuronal acetylcholine receptor; alpha3/beta4 | Ion channel | NEGATIVE ALLOSTERIC MODULATOR | Ki | 6.22 | WOMBAT-PK | CHEMBL | |||
| Neuronal acetylcholine receptor; alpha2/beta4 | Ion channel | IC50 | 5.51 | CHEMBL | |||||
| Neuronal acetylcholine receptor; alpha4/beta2 | Ion channel | Ki | 5.60 | WOMBAT-PK | |||||
| Neuronal acetylcholine receptor; alpha3/beta2 | Ion channel | IC50 | 6.55 | CHEMBL | |||||
| Neuronal acetylcholine receptor; alpha4/beta4 | Ion channel | BLOCKER | IC50 | 6.48 | IUPHAR | ||||
| Neuronal acetylcholine receptor; alpha3/alpha6/beta2/beta3 | Ion channel | IC50 | 4.96 | CHEMBL | |||||
| Acetylcholine receptor subunit alpha | Ion channel | BLOCKER | IC50 | 5.82 | IUPHAR | ||||
| Neuronal acetylcholine receptor subunit alpha-3 | Ion channel | BLOCKER | IC50 | 6.41 | IUPHAR | ||||
| Neuronal acetylcholine receptor subunit alpha-4 | Ion channel | BLOCKER | IC50 | 6.48 | IUPHAR | ||||
| Neuronal acetylcholine receptor subunit alpha-7 | Ion channel | Ki | 5.16 | WOMBAT-PK | |||||
| Neuronal acetylcholine receptor subunit alpha-6 | Ion channel | BLOCKER | IC50 | 4.96 | IUPHAR | ||||
| Acetylcholine receptor subunit alpha | Ion channel | IC50 | 6.22 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4019807 | VUID |
| N0000147896 | NUI |
| D00611 | KEGG_DRUG |
| 4017929 | VANDF |
| 4019807 | VANDF |
| C0025029 | UMLSCUI |
| CHEBI:6706 | CHEBI |
| CHEMBL267936 | ChEMBL_ID |
| DB00657 | DRUGBANK_ID |
| CHEMBL1237082 | ChEMBL_ID |
| D008464 | MESH_DESCRIPTOR_UI |
| 4032 | PUBCHEM_CID |
| 542 | INN_ID |
| 3990 | IUPHAR_LIGAND_ID |
| 826-39-1 | SECONDARY_CAS_RN |
| 6EE945D3OK | UNII |
| 6673 | RXNORM |
| 5027 | MMSL |
| d00739 | MMSL |
| 000655 | NDDF |
| 004499 | NDDF |
| 2991007 | SNOMEDCT_US |
| 372828008 | SNOMEDCT_US |
| 73277004 | SNOMEDCT_US |
| 6147-18-8 | SECONDARY_CAS_RN |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Mecamylamine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0722-7183 | TABLET | 2.50 mg | ORAL | ANDA | 19 sections |
| Vecamyl | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69413-558 | TABLET | 2.50 mg | ORAL | ANDA | 19 sections |
| Mecamylamine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 79739-7183 | TABLET | 2.50 mg | ORAL | ANDA | 19 sections |
| Vecamyl | HUMAN PRESCRIPTION DRUG LABEL | 1 | 83649-558 | TABLET | 2.50 mg | ORAL | ANDA | 19 sections |